Market Overview

UPDATE: JMP Securities Initiates Coverage on BIND Therapeutics on Recipe for Significant Value Creation


In a report published Tuesday, JMP Securities analyst Michael G. King initiated coverage on BIND Therapeutics (NASDAQ: BIND) with a Market Outperform rating and $30.00 price target.

In the report, JMP Securities noted, “Initiating coverage of BIND Therapeutics with a Market Outperform rating and year-end 2014 price target of $30, based on the synthesis of our DCF, standardized CAGR, and comparable company valuation methodologies. BIND Therapeutics is a development-stage, oncology-focused, drug development company that is leveraging its nanomedicine platform to improve the therapeutic profile of established oncology drugs. In our view, BIND's combination of a unique and proprietary technology platform, along with a seasoned and successful management team, is a recipe for significant value creation. The company's leading oncology asset, BIND-014, is BIND's Accurin-enabled version of the blockbuster oncology drug, docetaxel (Taxotere) which, prior to patent expiration in 2010, sold $3.1 billion worldwide for Sanofi (SNY, NC). BIND recently raised $70.5MM in an IPO to fund the program through to the start of Phase III development.”

BIND Therapeutics closed on Monday at $15.27.

Latest Ratings for BIND

Apr 2016Cowen & Co.DowngradesOutperformMarket Perform
Apr 2016JMP SecuritiesDowngradesMarket OutperformMarket Perform
Mar 2016JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for BIND
View the Latest Analyst Ratings

Posted-In: JMP Securities Michael G. KingAnalyst Color Initiation Analyst Ratings


Related Articles (BIND)

View Comments and Join the Discussion!

Latest Ratings

BIIBCantor FitzgeraldDowngrades0.0
WEXSunTrust Robinson HumphreyMaintains215.0
GISCredit SuisseMaintains52.0
OWells FargoMaintains78.0
HASWells FargoMaintains82.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: JMP Securities Initiates Coverage on Lpath on Potential of iSONEP and ASONEP

UPDATE: Nomura Initiates Coverage on FireEye with Buy Rating, $51 PT on Good Market Position